Research Bendamustine for treatment of iNHL and MCL Lymphoma is the fifth most common malignancy in Canada that is expected to cause 2800…lauradDecember 1, 2012
Research Rituximab and Elderly Mantle Cell Patients A study published in the New England Journal of Medicine showed that maintenance theraphy with…lauradDecember 1, 2012
Research Bendamustine added to BC Drug Benefit List The BC Cancer Agency, in the November 2012 Systemic Therapy Update, has added bendamustine (Treanda®)…lauradNovember 13, 2012
Research New Treatment Option for Relapsed Indolent B-cell Non-Hodgkin Lymphoma MONTREAL, QUEBEC, Sep 13, 2012 (MARKETWIRE via COMTEX) -- Editors note: There is a video…lauradSeptember 13, 2012
News World Lymphoma Awareness Day 2012 2012 World Lymphoma Awareness Day Saturday, September 15, 2012 We are extremely proud to be…lauradSeptember 13, 2012
News New Staff Announcement Vaughan Reid as National Development Manager and Charlene Ragin as Marketing and Communications Coordinator. (more…)lauradSeptember 7, 2012
Research Report Card on Wait Times In Canada Released The absence of a concerted national effort to reduce wait times is undermining progress on…lauradJune 25, 2012
Research New Program Launched For Safe Medication Use. Seven of Canada's leading health care organizations have joined together to launch new electronic tools…lauradJune 25, 2012
Research 2011-2012 Report Card on Cancer in Canada THE CANCER ADVOCACY COALITION OF CANADA (CACC), IN ITS ANNUAL REPORT CARD ON CANCER IN…lauradApril 11, 2012
News Lymphoma Canada conducts an important survey In September 2011, Lundbeck Canada Inc. filed a New Drug Submission (NDS) for bendamustine (Treanda®)…lauradMarch 21, 2012